Free tool
FAERS Monitor: Qvar Redihaler
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207921 or its brand name (Qvar Redihaler, Beclomethasone Dipropionate). Reports on generic versions are filed under their own applications.
Reports
2,861
Serious
697
24% of reports
Hospitalization
212
Death reported
37
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective393
- asthma346
- dyspnoea324
- cough265
- device malfunction255
- device delivery system issue194
- device issue178
- product use in unapproved indication126
- headache125
- wrong technique in product usage process112
- product dose omission issue108
- fatigue99
- product substitution issue97
- covid-1996
- malaise94
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 355 |
| 2019 | 475 |
| 2020 | 349 |
| 2021 | 308 |
| 2022 | 349 |
| 2023 | 282 |
| 2024 | 331 |
| 2025 | 235 |
| 2026 | 174 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,298 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device delivery system issueSignal | 194 | 52.5 | 45.8 | 9,685 |
| device malfunctionSignal | 255 | 26.8 | 23.8 | 6,298 |
| asthmaSignal | 346 | 22.6 | 20.4 | 7,129 |
| device issueSignal | 178 | 14.6 | 12.7 | 2,250 |
| product substitution issueSignal | 97 | 12.4 | 10.2 | 1,007 |
| coughSignal | 265 | 7.0 | 6.2 | 1,361 |
| dyspnoeaSignal | 324 | 4.2 | 3.8 | 811 |
| wrong technique in product usage processSignal | 112 | 4.1 | 3.4 | 258 |
| covid-19Signal | 96 | 4.0 | 3.3 | 217 |
| product use in unapproved indicationSignal | 126 | 3.7 | 3.2 | 253 |
| product dose omission issueSignal | 108 | 2.7 | 2.2 | 116 |
| drug ineffectiveSignal | 393 | 2.2 | 2.0 | 271 |
| malaise | 94 | 1.6 | 1.3 | 20 |
| headache | 125 | 1.5 | 1.2 | 19 |
| fatigue | 99 | 0.9 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.